Tyra Biosciences appoints Adele M. Gulfo to board; Nina Kjellson resigns

Tyra Biosciences, Inc.

Nina Kjellson resigned from board and Compensation Committee effective Jan 29, 2025, not due to disagreement.
Adele M. Gulfo appointed as Class I director and to Compensation Committee effective same date.
Gulfo, 62, former CEO Sumitomo Pharma America Biopharma Commercial Unit (Jul 2023-Oct 2024) and prior roles at Sumitovant, Roivant, Mylan, Pfizer, AstraZeneca.
Gulfo received options for 37,200 shares vesting over 36 months and cash compensation per non-employee director program.
Board determined Gulfo independent under Nasdaq rules; no material transactions with company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Adele M. Gulfo

Director

TYRA · Tyra Biosciences, Inc.

Effective: 2025-01-29
Filed: January 29, 2025, 6:59 PM ET

the Board appointed Adele M. Gulfo as a director of the Board, filling the Class I vacancy on the Board resulting from Ms. Kjellson’s resignation.

Departed

Nina Kjellson

Director

TYRA · Tyra Biosciences, Inc.

Effective: 2025-01-29
Successor: Adele M. Gulfo
Filed: January 29, 2025, 6:59 PM ET

Nina Kjellson resigned from the Board and the Compensation Committee of the Board effective as of January 29, 2025

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Adele M. Gulfo was appointed as Director at Tyra Biosciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Adele M. Gulfo as a director of the Board, filling the Class I vacancy on the Board resulting from Ms. Kjellson’s resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Nina Kjellson resigned as Director at Tyra Biosciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

Nina Kjellson resigned from the Board and the Compensation Committee of the Board effective as of January 29, 2025

View on SEC.gov

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-015646

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.